In yesterday’s Wall Street session, Codiak BioSciences Inc. (NASDAQ:CDAK) shares traded at $0.48, down -21.81% from the previous session.
As of this writing, 1 analysts cover Codiak BioSciences Inc. (NASDAQ:CDAK). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $9.00 and a low of $1.40, we find $7.00. Given the previous closing price of $0.62, this indicates a potential upside of 1029.03 percent. CDAK stock price is now -19.86% away from the 50-day moving average and -64.34% away from the 200-day moving average. The market capitalization of the company currently stands at $14.39M.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
There are 0 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $5.80 as their price target over the next twelve months.
With the price target of $19, Goldman recently initiated with Buy rating for Codiak BioSciences Inc. (NASDAQ: CDAK). On November 09, 2020, Wedbush recently initiated its ‘Outperform’ rating on the stock quoting a target price of $19, while ‘Goldman’ rates the stock as ‘Buy’.
In other news, WILLIAMS DOUGLAS E, President & CEO sold 7,681 shares of the company’s stock on Feb 17. The stock was sold for $4,549 at an average price of $0.59. Upon completion of the transaction, the President & CEO now directly owns 49,322 shares in the company, valued at $23674.56. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 17, Chief Financial Officer Bain Linda sold 2,570 shares of the business’s stock. A total of $1,522 was realized by selling the stock at an average price of $0.59. This leaves the insider owning 13,412 shares of the company worth $6437.76. Insiders disposed of 43,943 shares of company stock worth roughly $21092.64 over the past 1 year. A total of 0.48% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CDAK stock. A new stake in Codiak BioSciences Inc. shares was purchased by EMPERY ASSET MANAGEMENT, LP during the first quarter worth $115,000. VIRTU FINANCIAL LLC invested $25,000 in shares of CDAK during the first quarter. In the first quarter, CITADEL ADVISORS LLC acquired a new stake in Codiak BioSciences Inc. valued at approximately $16,000. TWO SIGMA INVESTMENTS, LP acquired a new stake in CDAK for approximately $14,000. TWO SIGMA ADVISERS, LP purchased a new stake in CDAK valued at around $7,000 in the second quarter. In total, there are 67 active investors with 71.70% ownership of the company’s stock.
Monday morning saw Codiak BioSciences Inc. (NASDAQ: CDAK) opened at $0.3700. During the past 12 months, Codiak BioSciences Inc. has had a low of $0.30 and a high of $7.15. As of last week, the company has a debt-to-equity ratio of 0.66, a current ratio of 4.20, and a quick ratio of 4.20. The fifty day moving average price for CDAK is $0.6038 and a two-hundred day moving average price translates $1.3494 for the stock.
The latest earnings results from Codiak BioSciences Inc. (NASDAQ: CDAK) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.77, beating analysts’ expectations of -$0.82 by 0.05. This compares to -$0.97 EPS in the same period last year. The net profit margin was -51.10% and return on equity was -37.60% for CDAK. The company reported revenue of $0.52 million for the quarter, compared to $1.16 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -54.88 percent. For the current quarter, analysts expect CDAK to generate $680k in revenue.
Codiak BioSciences Inc.(CDAK) Company Profile
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
